Skip to Main Content

Paper Details

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma.
Cancer Immunol Res
2
2023
BRAF, BRAF-inhibited tumors, BRAF-mutant melanoma, Braf, BrafV600E, Cxcl9, MEK, MRD, Melanoma, Patients, T, T-cell, chemokine, drug-tolerant tumor cells, effector T cells, melanoma, mouse, rCxcl9, recombinant Cxcl9, tumor, tumors
Author NameAffiliation
Alexander J LazarUniversity of Texas MD Anderson Cancer Center
Alexander J LazarUniversity of Texas MD Anderson Cancer Center
Jennifer A WargoUniversity of Texas MD Anderson Cancer Center
James C CostelloUniversity of Colorado Anschutz Medical Campus
Lawrence N KwongUniversity of Texas MD Anderson Cancer Center
  • 1 - 5

Datasets

Release 1.2